# Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients

> **NCT04352465** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Azidus Brasil** · enrollment: 42 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Methotrexate
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT04352465
- **Lead sponsor:** Azidus Brasil
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-01
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-11-30
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2020-04-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04352465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04352465, "Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT04352465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*